Results 261 to 270 of about 3,617,077 (391)

Palliative medicine: is it really specialist territory? [PDF]

, 1999
D M Buckley
openalex   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Medicines for treatment of older people in guidelines and essential medicines lists, WHO African Region. [PDF]

Bull World Health Organ
Foong KW, Paveley A, Alcock I, Gorejena-Chidawanyika P, Gregson CL, Pearson GM.   +5 more
europepmc   +1 more source

Exercise medicine : un nouveau concept ?

, 2017
Gilles Caty
openalex   +1 more source

Decision-Making Preferences and Deprescribing: Perspectives of Older Adults and Companions About Their Medicines

The journals of gerontology. Series B, Psychological sciences and social sciences, 2018
K. Weir, B. Nickel, V. Naganathan, C. Bonner, K. McCaffery, S. Carter, A. McLachlan, J. Jansen   +7 more
semanticscholar   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Factors influencing pharmaceutical companies' decisions to pursue compassionate use programs in the EU: a qualitative study in The Netherlands. [PDF]

J Pharm Policy Pract
Timmerman A, Rodenhuis N, Crane-van Opstal LMA, de Boer A, Bongers L, Pasmooij AMG.   +5 more
europepmc   +1 more source

Innovative Packaging of Medicines

, 2020
Poonam Madhukar Kasar, Cynthia Sunil Tribhuwan, Jyoti Gokul Khode   +2 more
openalex   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Fringe Medicine

BMJ, 1960
openaire   +2 more sources